SAN FRANCISCO -- Elan (ELN) said in a breakout session Tuesday at the J.P. Morgan Healthcare Conference that it is considering all options: strategic partners, selling off certain assets, a merger and an outright sale.The latter option seems a very remote possibility, mainly because Elan has well over $1 billion in debt coming due in 2011. That's not a nut potential suitors are going to want to take on right now. Take note, too, that if Elan is sold, Biogen Idec ( BIIB - Get Report), the company's Tysabri marketing partner, gets negotiating rights to wrest away full control of the drug. Elan shares have been strong this year, in part because of semi-persistent rumors that Pfizer ( PFE - Get Report) was interested in buying the company. After the last two days of meeting here, Elan management appears to have pretty much put that rumor to bed. I'm having breakfast with Elan management tomorrow, including CEO Kelly Martin, whom I named Worst Biotech CEO of 2008. Perhaps I should bring my own oatmeal?
More from Stocks
Avoid the 'Lunacy' of After-Hours Trading, Jim Cramer Says
Jim says after-hours action can be 'crazy' -- just look at what happened when Palo Alto Networks reported earnings.
Should Investors Be Optimistic About U.S.-China Trade Talks?
Need some advice when it comes to U.S.-China trade talks?
Biometric Passwords Are About to Go Big Time; Here's Who's Set to Profit
Diebold Nixdorf is best known for its 35% global market share of automated teller machines, but it is successfully branching out into digital verification.